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Abstract The metabolic composition of human biofluids
can provide important diagnostic and prognostic informa-
tion. Among the biofluids most commonly analyzed in
metabolomic studies, urine appears to be particularly useful.
It is abundant, readily available, easily stored and can be
collected by simple, noninvasive techniques. Moreover,
given its chemical complexity, urine is particularly rich in
potential disease biomarkers. This makes it an ideal biofluid
for detecting or monitoring disease processes. Among the
metabolomic tools available for urine analysis, NMR spec-
troscopy has proven to be particularly well-suited, because
the technique is highly reproducible and requires minimal
sample handling. As it permits the identification and quan-
tification of a wide range of compounds, independent of
their chemical properties, NMR spectroscopy has been fre-
quently used to detect or discover disease fingerprints and
biomarkers in urine. Although protocols for NMR data
acquisition and processing have been standardized, no con-
sensus on protocols for urine sample selection, collection,
storage and preparation in NMR-based metabolomic studies
have been developed. This lack of consensus may be leading
to spurious biomarkers being reported and may account for a
general lack of reproducibility between laboratories. Here,
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we review a large number of published studies on NMR-
based urine metabolic profiling with the aim of identifying
key variables that may affect the results of metabolomics
studies. From this survey, we identify a number of issues
that require either standardization or careful accounting in
experimental design and provide some recommendations for
urine collection, sample preparation and data acquisition.
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1 Introduction
Human diseases lead to pathophysiological changes that, in
turn, lead to variations in the concentrations of metabolites
in tissues and biological fluids. Metabolomics is a powerful
approach that permits the global monitoring of metabolite
levels when a living system responds to environmental
effects, physiological stimuli and/or genetic modifications.
As a result, metabolomics represents a powerful technique
for disease fingerprinting and biomarker discovery and for
the identification of perturbed biochemical pathways.
Furthermore, metabolomic data can be integrated with
genomic, transcriptomic and proteomic data to improve our
understanding of disease etiology and thereby optimize
treatment interventions (Yizhak et al. 2010; Griffin 2006;
Tang et al. 2009; Nambiar et al. 2010; Rantalainen et al.
2006). In many cases, the changes in urine metabolite
concentrations induced by human diseases can be greater
than the changes seen in protein levels, giving metabolo-
mics an extra diagnostic advantage (Kell 2006; Urbanczyk-
Wochniak et al. 2003; Raamsdonk et al. 2001; Cascante
et al. 2002). Thus, measuring metabolite profiles in human
urine has the potential to be used as an effective method to
diagnose a number of diseases and to monitor an individ-
ual’s general health status. Indeed, urine represents an ideal
biofluid for metabolomics studies because it captures and
concentrates a wide range of metabolites and metabolic
processes occurring throughout the body. As a conse-
quence, urine is particularly useful in providing specific
biomarkers for disease, toxicity and drug metabolism.
Urine’s non-viscous character combined with the fact that
it can be obtained non-invasively, in large quantities and
that it contains fewer protein complexes and lipids than
other body fluids (such as blood) has long made it a favored
biofluid for many metabolomics applications.
Metabolite profiles in biofluids may be measured using
several techniques including high performance liquid chro-
matography (Al-Talla et al. 2011a, b; Li et al. 2013; Nie et al.
2014; Szultka et al. 2014; Lan et al. 2010; Liang et al. 2010;
Zheng et al. 2010), tandem mass spectrometry (Guo et al.
2013; Huang et al. 2013b; Vadla et al. 2013; Allard et al.
2008; Chen et al. 2009; Cho et al. 2009), gas chromatography
with mass spectrometry (Karamani et al. 2013; Zheng et al.
2013; Jobu et al. 2012; Weusten et al. 2012; Xie et al. 2012;
Kumar et al. 2010; Qiu et al. 2010; Sun et al. 2009) and NMR
spectroscopy (Kim et al. 2013; Wang et al. 2013a; Bertram
et al. 2011; Duarte and Gil 2012; He et al. 2012; Calvani et al.
2010; Liu et al. 2010; Zhang et al. 2010; Michell et al. 2008;
Wishart 2008; Zhang et al. 2008). Each approach has its own
advantages and disadvantages, with some techniques being
better for analyzing certain biofluids than others. NMR, in
particular, permits the visualization of thousands of distinct
peaks and enables the detection and quantification of more
than 200 compounds in human urine (Bouatra et al. 2013). As
a consequence, metabolic profiling of human urine by NMR
spectroscopy has been used to discover a number of novel
biomarkers that can be used for disease diagnosis, prognosis,
prediction, and monitoring (Nevedomskaya et al. 2012; Pu
et al. 2012; Sachse et al. 2012; Zhang et al. 2012; Carrola
et al. 2011; Jung et al. 2011; Sengupta et al. 2011; Maher
et al. 2009; Tzovaras et al. 2009).
To date, most metabolomic studies of urine and human
disease have been designed as ‘‘case–control’’ studies in
which urine samples from patients are compared with
healthy controls. However, due to the environmental and
genetic diversity of human populations and to day-to-day
variability, comprehensive and robust metabolomic ana-
lysis of urine is a non-trivial task. In addition, study designs
(e.g., single or multiple collections), and especially pre-
analytical procedures, are generally not standardized,
thereby making inter-laboratory comparisons difficult.
Likewise, few studies take advantage of NMR spectros-
copy’s ability to obtain a metabolic fingerprint and to
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accurately determine multiple metabolite concentrations.
NMR can also be used to obtain a complete spectral fin-
gerprint of a given biofluid, thereby capturing all of the
NMR-detectable signals or features. In this way, it is
possible to obtain metabolic information without neces-
sarily knowing the exact composition of the samples or
signal assignment, so that multivariate data analyses can be
performed on the spectra to build statistical models for a
diagnostic/prognostic purpose.
A number of urinary metabolomics studies have repor-
ted biomarkers that effectively discriminate between dis-
eased subjects and healthy controls (Dawiskiba et al. 2014;
Bernini et al. 2011a; Fanos et al. 2013; Wen et al. 2010;
Duarte et al. 2014; Fanos et al. 2012; Weiss and Kim
2012). However, most of the biomarkers described so far
have not been validated nor have they been proven to be
truly specific to the disease that was studied. Furthermore,
the lack of standardized protocols in many urine studies
that distinguish patients from healthy controls is potentially
leading to erroneous results arising from the significant
contributions of major confounding factors such as diet,
age and gender. To identify a reliable disease biomarker or
to determine a discriminating metabolic fingerprint, it is
crucial to control for and understand all factors that may
alter the normal composition of human urine, so that nor-
mal metabolic fluctuations are not confused with patho-
logical changes. In order to minimize the effect of
confounding factors, it is crucial to conduct such studies
under standardized conditions that would allow researchers
from different groups to compare and validate their results.
Most importantly, standardization will allow researchers
from different parts of the world to store metabolite data
from urine in newly emerging metabolomics databases
such as MetaboLights and the Human Metabolome Data-
base (HMDB) (Haug et al. 2013; Salek et al. 2013a, b;
Wishart et al. 2007, 2009), which will enable direct com-
parisons of various studies.
Metabolomic analysis of urine samples has been suc-
cessfully used to identify a variety of metabolomic fin-
gerprints and potential biomarkers under a range of
different conditions. An exhaustive review of this literature
is beyond the scope of the present review. Instead, some
key examples are highlighted to illustrate the potential
power of the approach. An area of extensive research is the
study of cancer biomarkers, including the development of
putative biomarkers for bladder cancer (Alberice et al.
2013; Zhang et al. 2012), lung cancer (Carrola et al. 2011),
prostate cancer (Duarte and Gil 2012; Kumar et al. 2014),
liver cancer (Chen et al. 2011), colorectal cancer (Wang
et al. 2010), esophageal cancer (Davis et al. 2012), and
kidney cancer (Huang et al. 2013c; Weiss and Kim 2012;
Kim et al. 2011; Ganti and Weiss 2011). Examples of the
metabolites identified as putative biomarkers of kidney
cancer include acylcarnitines, quinolinate, gentisate, and
4-hydroxybenzoate. Application of metabolomics in cancer
staging has recently emerged and its importance is expec-
ted to grow in the coming years (Kim et al. 2011).
Applications of urine metabolomics to the study of
inflammatory bowel disease (IBD) has also been successful
from a diagnostic viewpoint. A number of studies have
reported metabolomic profiles that are capable of separat-
ing subjects with IBD subtypes from healthy controls
(Schicho et al. 2012). More recently, an NMR based pro-
filing of urine samples demonstrated the ability to distin-
guish patients with active IBD from those with IBD in
remission (Dawiskiba et al. 2014). Other conditions such as
heart failure also appear to be detectable through urine-
base metabolomics. Proton NMR spectra of the urine of 15
patients with ischemic heart failure (HF) were compared
with the proton NMR spectra of the urine of 20 healthy
controls. The results show clear separation between the
patient samples and healthy ones, where the HF patient
samples had higher concentrations of metabolites such as
acetate and acetone compared with the healthy control
samples. On the other hand, the HF patients’ urine had
decreased levels of 1-methylnicotinamide and increased
levels of methylmalonic acid, cytosine and phenylacetyl-
glycine compared to the healthy controls (Kang et al.
2011). It was reported that the perturbation of these
metabolites could be related to TCA cycle metabolites and
fatty acid metabolism (Kang et al. 2011). Applications of
the metabolomics-based approach in the field of human
toxicology have also yielded positive results. An example
is the study of acetaminophen-induced hepatoxicity. A
number of studies have identified metabolic signatures
associated with hepatoxicity (Kim et al. 2013; Clayton
et al. 2006). Overall, the above examples and additional
examples included in Table 1 highlight the potential use of
metabolomics analysis of urine for disease diagnosis. For
progress of this discipline and to avoid the discovery of
false positives it is imperative that we have a good
understanding of the non-physiological factors influencing
metabolite levels in the urine.
To identify the key factors that contribute to the varia-
tions in human urine metabolic profiles, we have divided
this paper into two sections. In the first part of this review,
we highlight and compare a number of previously pub-
lished studies (Table 1) pertaining to NMR-based urine
metabolomics. In the second part of this review, we pro-
pose a number of recommendations that have the potential
to help minimize confounding effects, including subject
selection, sample collection and sample preparation, with
regard to NMR-based urine metabolomics. From this
overview, we hope to help other metabolomics researchers
appreciate the importance of developing global protocols to
standardize the collection, preparation, storage and analysis
874 A.-H. Emwas et al.
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Table 1 A randomly selected examples of urinary analysis studies using an NMR-based metabolomics approach with particular focus on the








pH Study description References
5 min 1,500 -80 7.4 Urine specimens were collected before and at 4 and 24 h after surgery




15 3,000 7.4 Urinary tract infections (UTI) studied by NMR of urine samples using a
longitudinal design. The study included four classes of samples
originating from controls (N = 35) at day 0 (baseline control), UTI
patients (N = 32) at day 0 (baseline), UTI patients (n = 29) at day 4
and UTI patients after recovery from infection (n = 37) at day 30
(Nevedomskaya
et al. 2012)
10 13,200 -80 7.4 NMR based metabolomics of urine differentiates dogs with bladder
cancer (n = 40) from healthy controls (n = 42)
(J. Zhang et al.
2012)
10 min 3184 -80 7.4 A NMR metabonomics study involving 447 individuals from Uganda,
infected by S. mansoni. Urines were collected at five time-points,
before and after chemotherapy with praziquantel
(Balog et al.
2011)
10 min 12,000 -70 7.0 Patients with systolic HF of ischemic origin (n = 15) and healthy




5 min 8,000 -80 7.0 1H NMR-based metabonomics was applied to investigate lung cancer
metabolic signatures in urine. Urine samples from lung cancer patients
(n = 71) and a control healthy group (n = 54) were analyzed by high
resolution 1H NMR (500 MHz). The classification model showed




10 min 7,000 7.0 In this study, age-related metabolic changes in children of age 12 years
and below were analyzed by NMR spectroscopy. Urine samples from
55 children, with no diagnosed disease, were collected and analyzed
(Gu et al. 2009)
10 min 2500 -20 NM Urine, plasma, and saliva were collected from 30 healthy volunteers (23
females, 7 males) on 4 separate mornings. For visits 1 and 2, free food
choice was permitted on the day before biofluid collection. Food
choice on the day before visit 3 was intended to mimic that for visit 2,
and all foods were standardized on the day before visit 4. Samples
were analyzed by using 1H NMR
(M. C. Walsh
et al. 2006)
5 min 10,000 -20 7.0 22 women were segregated into an untrained (n = 10) or trained
(n = 12) group depending on their physical training background. The
subjects performed two exercises in a randomized order: a prolonged
exercise test and a short-term, intensive exercise test. Urine specimens
were collected before and 30 min after each test. The samples were
analyzed by (1)H NMR spectroscopy
(Enea et al.
2010)
5 min 8000 NM 7.4 12 healthy male participants (age range of 25–74 years) consumed three
different diets, in a randomized order, for continuous 15-days-periods
with an intervening washout period between each diet of 7 days
duration. Each participant provided three consecutive 24-h urine
collections on days 13, 14, and 15 of each dietary period, and 1H
NMR spectra were acquired on all samples
(Stella et al.
2006)
5 13,400 NM 7.4 This study aimed to identify novel markers for gestational diabetes in
the biochemical profile of maternal urine using NMR metabolomics. It
also studied the general effects of pregnancy and delivery on the urine
profile. Urine samples were collected at three time points from 823
healthy, pregnant women and analyzed using (1)H-NMR spectroscopy
(Sachse et al.
2012)
NM NM NM 7.4 Changes in metabolism in volunteers living near a point source of
environmental pollution were investigated. NMR was used to acquire
urinary metabolic profiles from 178 human volunteers
(Ellis et al.
2012)










pH Study description References
10 12,000 -80 C 7.4 This study included 16 bilateral ureteral obstruction (BUO) patients and
nine unilateral ureteral obstruction (UUO) patients. The obstructions
in all of the patients were successfully relieved after treatment. Urine
samples at different time points before and after treatment were
obtained, and their (1)H NMR spectra were recorded
(Dong et al.
2013)
3 min 13,000 -20 7.0 ± 0.1 NMR-based metabolomics on blood serum and urine samples from 32






6.0 Study on the pharmacological effects of rosiglitazone in plasma and
urine samples from patients with type 2 diabetes mellitus (n = 16) and
healthy volunteers (n = 16)
(van Doorn et al.
2007)
NM NM -80 6.8 ± 0.1 Investigations of the effects of gender, diurnal variation, and age in
human urinary metabolome. 30 male and 30 female subjects aged
19–69 years, self-identified as healthy, participated in this study.
Individuals provided two urine samples a day, one as a first void and a
second at *5 p.m., for four nonconsecutive days
(Slupsky et al.
2007)
5 min 14,000 -80 7.0 About 40 urine samples (first in the morning, preprandial) were
collected from 20 healthy individuals (9 males, 11 females) in the age
range 25–55 over a period of about 3 months to demonstrated the
stability in time of the urinary metabolome
(Bernini et al.
2009)
NM NM -80 7.4 84 urine samples were collected from 12 healthy volunteers (7 time
points, 8 males and 4 females) and 50 samples from 30 T2DM patients
(1–3 time points, 17 males and 13 females)
(Salek et al.
2007)
NM NM NM NM A NMR based metabolomics investigation of Hepatitis C virus infection
identified 32 of the 34 patients in the disease group as positive and 31
of the 32 individuals in the control group as negative, demonstrating
94 % sensitivity and specificity of 97 %
(Godoy et al.
2010)
15 min 6,000 -80 7.4 Urine samples were collected from 119 Sardinian children (63 males, 56
females, average age 8.3 ± 2.9). Of these, 90 were healthy and 29
type 1 diabetic without complications, with average diabetes duration
of 5.2 ± 3.9 years
(Culeddu et al.
2012)
NM NM -20 4 A total of twenty-four 8-year-old boys were asked to take 53 g protein
as milk (n 12) or meat daily (n 12). At baseline and after 7 days, urine
and serum samples were collected and high-resolution 1H NMR
spectra were acquired on these using a 800 MHz spectrometer
(Bertram et al.
2007a)
5 min 1600 -20 6.0 The plasma and urine metabolome of 192 overweight 12–15-year-old
adolescents (BMI of 25.4 ± 2.3 kg/m2) were examined in order to
elucidate gender, pubertal development, physical activity and intra-/




10 12,000 NM 7.0 Serum and urine samples were collected from 24 patients with




10 12,000 -80 7.4 Urine samples were collected from 30 children and teenagers aged 4–19
with T1D and 12 healthy children, aged 9, as control group. Patients




10 3,000 -80 7.4 The urinary metabolic profiles of 30 autistic and 28 matched healthy
children were obtained using NMR-based approach
(Mavel et al.
2013)
10 20,000 -80 7.4 32 schizophrenia inpatients and 30 healthy volunteers were recruited.
Samples of patients were collected at baseline and weeks 3 and 6
during hospitalization. Samples of healthy controls were collected
only once following the same procedure
(Cai et al. 2012)
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of urine samples for the purpose of identifying disease
fingerprints and biomarkers.
2 NMR spectroscopy
NMR spectroscopy has played a key role in our under-
standing of metabolism and metabolic processes for more
than three decades (Eggleston et al. 1975; Gavaghan et al.
2000). Its exceptional capacity to resolve thousands of
peaks in complex metabolite mixtures such as blood and
urine is probably what led NMR to be the technology of
choice to initially develop the field of metabolomics
(Emwas et al. 2013a; Rasmussen et al. 2012; Bouatra et al.
2013; Psychogios et al. 2011). As an analytical technique,
NMR is a powerful approach for both identification and
quantification of analytes with a number of important
advantages, such as being highly reproducible, high-
throughput, non-destructive, and non-biased, not requiring
prior chromatographic separation, and, most importantly
requiring minimal sample preparation (Bouatra et al. 2013;
Monteiro et al. 2013; Zhang et al. 2013; Abuhijleh et al.
2009; Blindauer et al. 1997; Di Gangi et al. 2014). In
addition, unlike GC–MS (Bouatra et al. 2013; Huang et al.
2013a; van der Kloet et al. 2012; Abbiss et al. 2012; Ko-
tlowska et al. 2011; Kuhara et al. 2011) and certain liquid
chromatography–mass spectrometry (LC–MS) methods
(Bouatra et al. 2013; Huang et al. 2013; Lu et al. 2013;
Norskov et al. 2013; Boudonck et al. 2009; Gowda et al.
2009; Tsutsui et al. 2010), no chemical derivatization or
ionization are necessary. NMR is particularly amenable to
detecting polar and uncharged compounds, such as sugars,
amines or relatively small, volatile compounds (such as
formic acid, formaldehyde, acetone, etc., which are often
undetectable by LC–MS methods. Finally, multidimen-
sional and heteronuclear NMR techniques can be employed
for the unambiguous identification and characterization of
unknown compounds (Abuhijleh et al. 2009; Vestergren
et al. 2012; Bubb 2003; Mattar et al. 2004). The inherent
low sensitivity of NMR, however, restricts the detection
limit to about 1 lM and often necessitates the use of rel-
atively large sample volumes (*200–500 lL). New
micro-coil probes can reduce the sample volume to as low
as a few lL (Serkova et al. 2009; Krojanski et al. 2008;
Grimes and O’Connell 2011; Sukumaran et al. 2009).
Nevertheless, for urine, the sample volume is generally not
a problem. Overall, the numerous benefits of using NMR
far outweigh its sensitivity limitations. As a result, NMR is
now being used in clinical applications as well as medical
research including disease diagnosis, drug assessment and
personalized medicine (Emwas et al. 2013a; Nageeb et al.
2013). NMR is also being widely used in metabolite-based
biomarker discovery of several human diseases (Farshidfar
et al. 2012; Nahon et al. 2012; Mehrpour et al. 2013; Diaz
et al. 2013; Atzori et al. 2010; Culeddu et al. 2012; Ala-
Korpela 2007; O’Connell 2012; Nevedomskaya et al. 2012;
Sachse et al. 2012).
The technology behind NMR spectroscopy is quite
mature and most technological or equipment advances over
the past decade have been relatively incremental. The
developments in instrumentation, such as higher magnetic
field magnets (Gruetter et al. 1998), cryogenically cooled
probes (Keun et al. 2002), and microprobes (Grimes and
O’Connell 2011; Sukumaran et al. 2009), are some major
advancements that have enhanced the resolution and sen-









pH Study description References
10 12,000 -80 7.4 Serum and urine samples were collected from chronic obstructive
pulmonary disease patients (n = 32) and healthy controls (n = 21),




NM NM -25 5.0 1H NMR-based metabonomics was used for the detection and diagnosis
of inborn errors of metabolism from urine samples. 1D 1H NMR
spectra from 47 normal, 9 phenylketonuric newborns and 1 maple
syrup urine disease child were obtained and investigated.
(Constantinou
et al. 2005)
NM NM -20 NM The aim of this study was to assess the feasibility and comparability of
metabonomic data in clinical studies conducted in different countries
without dietary restriction. A group of healthy British subjects
(n = 120), and healthy subjects from two European countries (Britain
and Sweden, n = 30) were compared. The subjects were asked to




NM indicates not mentioned parameters
Standardizing the experimental conditions for using urine in NMR 877
123
development of note is called dynamic nuclear polarization
(DNP). DNP provides significant increases in the sensi-
tivity of NMR spectra (Ardenkjær-Larsen et al. 2003) and
has been used to measure very low-abundance metabolites
in several biological samples (Day et al. 2007; Emwas et al.
2008; Chekmenev et al. 2009; Ludwig et al. 2010). In
particular, Frydman et al. has developed a new method to
facilitate the use of DNP in NMR-based metabolomics
research (Harris et al. 2011). However, DNP metabolo-
mics, although intriguing as a technical improvement, is
still far from the reliability and accessibility needed for
routine analysis.
Although numerous types of NMR experiments are
readily available, simple one-dimensional (1D) proton (1H)
NMR spectroscopy has become the standard data collec-
tion technique for most NMR-based metabolomics studies.
As a data collection method, it is fast, simple, highly
reproducible and readily yields spectra that contain hun-
dreds or even thousands of peaks. However, the main
limitation of 1D 1H NMR spectroscopy is the fact that it
generates spectra with many overlapping signals. These are
due to the limited spectral dispersion of 1H chemical shifts,
which can lead to uncertainties in the assignment and
quantification of many metabolites. Other methods, such as
one-dimensional carbon (13C) NMR spectroscopy, exhibit
much greater spectral dispersion compared with 1H NMR
spectroscopy. As a result 13C NMR has been proposed as
an alternative method that can help overcome the spectral
overlap problem of 1H NMR (Mavel et al. 2013; Faiz et al.
2011; Rai and Sinha 2012). However, the low natural
abundance of 13C nuclei (1.1 %) and the low gyromagnetic
ratio contribute to the relatively low sensitivity of this
nucleus and hinder the widespread use of 13C in NMR-
based metabolomics applications.
3 The human urine metabolome
A comprehensive characterization of the human urine
metabolome has recently been published (Bouatra et al.
2013). Extensive literature reviews combined with exten-
sive experimental studies conducted across a variety of
metabolomic platforms (e.g., NMR, HPLC, GC–MS etc.)
found that more than 4,000 metabolites have been detected
in urine and that slightly more than 200 metabolites can be
routinely measured by NMR. Interestingly, of all the
platforms and technologies assessed in this study, NMR
was found to be the best—both in terms of coverage and
metabolite quantification. As noted in this study, one of the
main challenges of studying the human urine metabolome
is its inherently high variability. The metabolic composi-
tion of urine is affected by many factors, such as diet,
exercise, health status, gender, age, diurnal cycles, gut
microflora as well as an individual’s genetics. For example,
it has been reported that the metabolic composition of
human urine is influenced by geographic location and
dietary practices tied to specific cultures (Lenz et al. 2004).
In one study of note, NMR-based metabolomics was
employed to analyze urine samples obtained from residents
of Britain and Sweden (Lenz et al. 2004). Clearly detect-
able differences were found in the urine samples of the two
sub-groups, which were clearly attributable to dietary dif-
ferences between the two countries. This result demon-
strates the need to account for dietary data in urine
metabolomic studies and to the need for dietary data to be
used in the interpretation of any urine metabolomic study
conducted for diagnostic biomarker discovery. However,
even if the same individual is subjected to a strong, day by
day variability due to diet and lifestyle, multiple urine
collection allow one to average out this variability and to
define the individual invariant part of the metabolome
(Assfalg et al. 2008; Bernini et al. 2009).
4 Factors leading to changes in the type and levels
of metabolites in human urine
4.1 Diet effects
Because human urine is essentially a filtrate derived from
food, drink, endogenous metabolism, drugs, and other
products, different nutritional habits and host/guest inter-
actions with the gut microbiome lead to different metabolic
signatures in urine. Application of metabolomics to the
discovery of new dietary biomarkers has been extremely
fruitful in recent years, highlighting the important influence
of dietary factors on urinary profiles (Heinzmann et al.
2010; Lloyd et al. 2011). Over the past 15 years, several
NMR-based metabolomic studies have been conducted to
systematically explore the effects of different diets and
dietary components on the chemical composition of urine
(Walsh et al. 2006; Walsh et al. 2007; Stella et al. 2006;
Llorach-Asuncion et al. 2010; Llorach et al. 2009; Holmes
et al. 2008a; Fave et al. 2011; Winnike et al. 2009). In one
particularly important study, 1H NMR spectroscopy was
employed to study urine samples collected from ten healthy
volunteers who were admitted to a clinical research center
for 2 weeks of dietary standardization (Winnike et al.
2009). The results suggested that 24 h of dietary stan-
dardization could be enough to provide the normalization
necessary in a clinical research setting (Winnike et al.
2009). In another study, the results of analyzing the urine
of 30 healthy individuals revealed that the metabolic profile
in urine is more sensitive than other biofluids (plasma and
saliva) to acute dietary intake (Walsh et al. 2006). These
results show that dietary variation has the potential to be a
878 A.-H. Emwas et al.
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significant confounding factor in metabolic profiles of
urine and may interfere with disease biomarker studies.
More recently an NMR-based metabolomics study dem-
onstrated that dietary patterns were clearly reflected in
urinary metabolites, where O-acetylcarnitine was posi-
tively associated with red-meat consumption while
phenylacetylglutamine associated with vegetable intake
(O’Sullivan et al. 2011).
In a comprehensive study published in 2006, Nicholson
et al. combined NMR-based metabolomics with multivar-
iate statistical analysis to study the effects of three diets
(mostly meat, minimal meat and vegetarian) on human
metabolic phenotypes (metabotypes; see later) (Stella et al.
2006). This study was conducted with a long dietary
standardization period during which 12 healthy participants
consumed each diet continuously for 15 days followed by
7 days washout periods. Proton NMR spectra of the urine
samples collected from each participant on days 13, 14 and
15 were recorded under the same experimental conditions.
The results revealed the different urine metabolic signa-
tures of different diets. Higher levels of some metabolites,
such as carnitine, acetylcarnitine, and trimethylamine-N-
oxide (TMAO) were found to be associated with a mostly
meat diet (Stella et al. 2006). Furthermore, the urinary
concentration of creatine (a metabolite that is found mainly
in muscle tissue) was much higher in samples taken during
the mostly meat diet than in samples from the minimal
meat and vegetarian diets. On the other hand, p-hydroxy-
phenylacetate (a microbial/mammalian co-metabolite) was
elevated in the samples taken from those on a vegetarian
diet compared with samples taken from those on meat
diets. This indicates that urine is sensitive to alterations of
bacterial composition or metabolism in response to diet
(Stella et al. 2006). The most significant results of this
study were found in both the inter-individual and the intra-
individual differences in the metabolic signatures of urine,
with some participants showing a much greater metabolic
response to diet standardization than did other participants.
This confirms the effect of an individual’s metabotype on
his/her urinary metabolic fingerprint that has to be con-
sidered in urine biomarker investigations.
4.2 Effects of sample collection time
In a comprehensive study published in 2007, the effect of
the time of day on urine collection was evaluated (Slupsky
et al. 2007). 1H NMR spectra of urine samples collected in
the morning were compared with proton NMR spectra of
samples collected from the same subjects in the afternoon.
The concentrations of some metabolites, such as creatinine,
mannitol, dimethylamine, 1-methylnicotinamide, xylose,
and acetone, differed between the samples collected in the
morning versus the samples collected in the afternoon
(Slupsky et al. 2007). In another study, it was found that the
concentration levels of 4-aminohippurate, aspartate, crea-
tine, formate, glutamate, phenylalanine, salicylurate, tryp-
tophan, and transaconitate were found to be different
between morning and afternoon urine collection (Saude
et al. 2007). The effects of collection time on metabolite
concentration levels in human urine have been reported by
other studies, suggesting that the sample collection time
should be standardized in any urine metabolomics study
(Maher et al. 2009; Saude et al. 2007). In general, it is
reasonable to collect urine samples in the usual cups or
vacutainers used for the common clinical urinalysis. To
avoid potential chemical contaminant variations coming
from the containers or filters, ideally one should try to use
the same kind/brand of containers and filters for the dura-
tion of a given project.
4.3 Age and gender effects
Proton NMR spectroscopy was employed to study the
effect of gender and age on the metabolic composition of
urine (Kochhar et al. 2006; Faughnan et al. 2004; Gava-
ghan et al. 2000). In one study, the age of 40 was chosen as
a threshold between young and old. The results demon-
strated that proton NMR spectra can distinguish young and
old subjects, suggesting that age plays a determining role in
urine metabolite levels. Several metabolites, such as car-
nitine, 3-hydroxyisovalerate, creatinine, alanine, and trig-
onelline, could be used to distinguish the samples from
young and old subjects (Slupsky et al. 2007). In another
study, Kochhar et al. used NMR spectroscopy to analyze
urine samples from 150 healthy participants to investigate
the effects of gender, age and body mass index (BMI) on
the metabolic signatures found in human urine. The results
showed that the metabolic signatures in urine could be
distinguished based on gender, age and BMI. Taurine,
creatinine, and citrate could distinguish the gender of the
subjects with taurine and creatine/creatinine concentrations
being more elevated in urine from males, whereas citrate
concentrations were elevated in the urine from females
(Kochhar et al. 2006). Glycine, citrate, creatine/creatinine,
dimethylamine, and other unidentified metabolites could be
used to distinguish the age of the subjects. Gender meta-
bolomic signatures in urine have also been demonstrated in
other metabolomics studies (Duarte and Gil 2012; Faugh-
nan et al. 2004; Psihogios et al. 2008).
4.4 Human metabolic phenotypes (metabotypes)
Determining an individual’s unique personal phenotype
could be particularly useful in clinical and therapeutic
applications such as personalized medicine and for fol-
lowing disease progression and enabling early diagnosis
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and prevention. Individual phenotypes may be different not
only because individuals are genetically different, but also
because of different environmental factors. Thus, the phe-
notype could be more relevant than the genotype when
dealing with disease pathologies and individual responses
to drug intervention or other external environmental stim-
uli. From an NMR-based metabolomics study of animal
urine samples, Gavaghan et al. proposed the existence of
unique metabolic phenotypes termed metabotypes (Gava-
ghan et al. 2000). A metabotype was defined as ‘‘a prob-
abalistic multiparametric description of an organism in a
given physiological state based on analysis of its cell types,
biofuids or tissues’’ (Gavaghan et al. 2000).
By means of repeated sampling at different days in the
same individual (multiple samples approach), Assfalg et al.
provided evidence that individual phenotypes do exist.
They investigated 873 human urine samples collected from
22 healthy subjects over 3 months (Assfalg et al. 2008).
Samples collected from a subset of the same individuals 2
and 3 years after the initial study provided additional proof
of the existence of individual metabotypes and showed that
the metabolic fingerprint is stable over a time period of at
least 2 or 3 years (Bernini et al. 2009; Blindauer et al.
1997). Furthermore, anecdotal evidence was reported
indicating that identical twins can share very similar met-
abolic phenotypes (Bernini et al. 2009). Furthermore, the
results demonstrated that an individual’s metabolic phe-
notype is affected by both the gut microbiome and host
metabolic metabotypes (Bernini et al. 2009).
The multi-sample approach for characterizing an indi-
vidual’s metabolic fingerprint opens the door to a new
approach for biomedical research. In particular, whereas
the metabolic snapshot (single sample) approach is gener-
ally used to study correlations between pathologies and the
metabolome by comparing the differences between the
metabolites found in a group of healthy individuals and a
group of patients, the multiple-sample approach can be
used to more accurately assess inter-person variability. It
can also be used to take into account variations linked to
disease development or progression, changes in lifestyle or
stress response. In this way, an individual can act as a
control for him/herself, increasing the power of the ana-
lysis. Multi-sample collection from the same individual
over a long period of time will allow following disease
onset/progression and the evaluation of the individual
response to therapeutic intervention.
4.5 Gut microflora effects
The human body is known to be a host for numerous and
complex consortia of microorganisms, many of which are
found in the gut (Nicholson et al. 2012; Blumberg and
Powrie 2012; Holmes et al. 2012). It has been reported that
the development of an individual’s microbiome starts at
birth when the microbial landscape (seed ecology) is pas-
sed from mother to child. After birth, it starts to take shape,
subject to several factors, such as diet, lifestyle, use of
antibiotics and pathological states (Ravel et al. 2011;
Torrazza and Neu 2011; Nicholson and Wilson 2003). For
example, intestinal bacteria are associated with the patho-
genesis of several diseases, including irritable bowel syn-
drome (Martin et al. 2006), cardiovascular disease (Pereira
and Gibson 2002), insulin resistance (Dumas et al. 2006),
Crohn’s disease, gastrointestinal cancer (Dunne 2001), and
celiac disease (Tjellstroem et al. 2007). Gut microflora also
play a crucial role in regulating key physiological activi-
ties, such as processing and absorbing nutrients and the
metabolism of many xenobiotic compounds (Lee et al.
2012). Several studies have shown that high levels of
hippuric acid, and many other aromatic compounds
observed in the urine of animals, originate from gut
microbial metabolism of dietary polyphenols (Nicholls
et al. 2003; Williams et al. 2002). It was pointed out that
the gut is one of the important factors in determining the
host’s metabolic phenotype (McKee et al. 2006). Since the
outcomes of treatment interventions are influenced by an
individual’s metabolic phenotype for which the gut status
is a determining factor (Dumas et al. 2006), it has been
proposed that gut microorganisms should be considered as
part of personalized treatment solutions (Holmes et al.
2008b; Clayton et al. 2006; Nicholson et al. 2005).
Recently, NMR-based metabolomic approaches were used
to study the endogenous metabolic changes in the urine of
pseudo germ-free rats. Changes in the levels of 25
metabolites were associated with the activities of gut
microflora, highlighting the importance of gut microflora in
the metabolic composition of urine in disease-related
studies. All of the affected metabolites could be potential
biomarkers (Lee et al. 2012). Recent studies (Bertini et al.
2009, 2011a) showed that, by applying NMR-based met-
abolomics to the study of celiac disease, several urinary
metabolites originating from gut microflora were found to
be significantly different between healthy controls and
celiac patients.
4.6 Physical activity
Human metabolism is directly associated with physical
activity. Such activity can affect the metabolic signature of
urine over both short and long time periods. 1H NMR-
based metabolomics approaches have been used to study
metabolomic modifications in urine after different kinds
and levels of physical activities (Enea et al. 2010). The
results showed that it was possible to distinguish between
urine samples collected before and after exercise, with
levels of lactate, pyruvate, alanine, b-hydroxybutyrate, and
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hypoxanthine increased after exercise (Enea et al. 2010).
1H NMR-based metabolomics combined with multivariate
statistical analysis could also differentiate the urine me-
tabolome of participants involved in two exercise sessions
which differed in the duration of the rest interval between
repeated exercise efforts, namely three sets of two 80 min
maximal runs separated by either 10 s or 1 min rest times
(Pechlivanis et al. 2010). Samples collected pre and post
exercise could be differentiated based on the metabolites
lactate, pyruvate, hypoxanthine, compounds of the Krebs
cycle, amino acids, and products of branched-chain amino
acid (BCAA) catabolism whilst samples from the different
rest intervals were separated via lactate, pyruvate, alanine,
compounds of the Krebs cycle, 2-oxoacids of BCAA, and
2-hydroxybutyrate with higher amounts of these metabo-
lites in samples from the shorter rest time. The authors
attribute these increased metabolite levels to the greater
metabolic disturbances arising from very limited recovery
time (10 s) between each run, and highlight the potential
role of metabolomics in enhancing knowledge of exercise
physiology.
4.7 Interactions between factors that affect metabolite
levels
The factors that affect metabolite concentration levels in
human urine can be divided into two categories. The first
category represents the factors that cannot be controlled
such as age, gender, metabotype and gut microflora while
the second category represents the factors that can be con-
trolled such as diet, sample collection methods, sample
storage and sample preparation and therefore require stan-
dardization. However, these factors are not completely
independent. Indeed they can significantly influence each
other, which further complicates disease diagnostic studies.
For example, the level of hippurate, which is one of the most
abundant metabolites in human urine, can be influenced by a
wide range of physical, emotional and dietary effects. Sub-
stantial variations in hippurate levels have been associated
with different psychiatric disorders disorders with decreased
levels in schizophrenia and depression and elevated hippu-
rate excretion levels during episodes of anxiety (Quastel and
Wales 1938; Fabisch and Fellner 1957; Johannsen et al.
1962; Persky et al. 1950). Increased levels of hippurate were
also found in the urine of type-I diabetic patients compared
with samples from healthy controls (Zuppi et al. 2002). In
another study, lower levels of hippurate were detected in
urine samples from 15 morbidly obese subjects compared
with samples collected from 10 healthy age-matched con-
trols (Calvani et al. 2010). Perturbations in urinary hippurate
levels were also reported in urine samples of children with
autism (Yap et al. 2010). The perturbation of hippurate
concentrations in human urine can be confusing in novel
disease biomarker identification or validation as several
diseases may lead to similar changes. Moreover other
unrelated cofactors can also lead to different changes in the
hippurate level. For example, elevated hippurate excretion
has long been associated with several dietary components
including tea, coffee, fruits and vegetables (Clifford et al.
2000; Cathcartrake et al. 1975). NMR-based metabolomics
studies have also revealed significant changes in hippurate
concentration levels in the urine of healthy subjects and
these changes correlated with the subject’s age (Psihogios
et al. 2008). Variation in the excretion levels of hippurate
has also been found to be gender-correlated where higher
hippurate concentrations were reported in the urine of
females compared with age-matched male subjects (Psiho-
gios et al. 2008; Siqueira and Paiva 2002). The effects of gut
microbiota on hippurate concentrations in human and animal
urine samples have been frequently reported (Nicholls et al.
2003; Nicholson et al. 2005; Cotran et al. 1960). Moreover,
these cofactors may influence each other when different
diets affect the gut microbiota excretions of hippurate (Lees
et al. 2013), leading to further complications in disease
diagnostic studies. Given these many influences, it is prob-
ably safe to say that hippurate cannot reasonably be used as
a novel biomarker for any condition.
5 Sample preparation and experimental conditions
There are many reasons for modified metabolic concen-
trations in human urine, including diet, drug administra-
tion, health conditions, physical activity and environmental
stressors. The collection of multiple samples from the same
donor over a relatively extended time period helps identify
the invariant part of the urine metabolome that character-
izes an individual’s metabotype (Gavaghan et al. 2000;
Bernini et al. 2009; Assfalg et al. 2008). On the other hand,
the pre-analytical treatment of urine samples may alter the
original metabolic profiles (Bernini et al. 2011b). The
major cause of pre-analytical variation in urine samples
arises from the presence of human or bacterial cells that
may break upon sample freezing (due to water crystal
formation) or arise from harsh centrifugation conditions
employed to remove particulate matter from urine samples
used in NMR. If cells are eliminated by filtration (or mild
centrifugation) before NMR sample preparation or long-
term storage, the unwanted effects can be easily attenuated.
Adding NaN3 to urine at the moment of collection, or just
before freezing the samples, is a recommended step in
many proteomics analysis protocols to avoid bacterial
growth (Thongboonkerd et al. 2006; Thomas et al. 2010) In
NMR metabolomic studies it is more common to store
samples without any preservative agent and to add sodium
azide at the time of sample preparation for NMR analysis
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(Saude and Sykes 2007). However, there are examples of
metabolomic studies where sodium azide was added
immediately after sample collection (Grison et al. 2013;
Ganti and Weiss 2011). It is well known that the presence
of bacteria can alter the metabolic profile of urine (Saude
and Sykes 2007), consequently it is recommended that
urine samples be collected midstream (thereby avoiding the
early urine flow that contains urethral contaminants)
(Lewis et al. 2013) which is also the standard way to col-
lect urine samples for clinical urinanalysis (Delanghe and
Speeckaert 2014).
5.1 Subject (sample) selection
While most metabolomic studies pay attention to factors
such as age, gender and diet, little information if any is
available about the criteria for the choice of healthy control
subjects. For comparative purposes, it is important that the
definition of normal or healthy subjects be uniform. While
there is a clear difference between someone being healthy
and someone simply lacking disease symptoms, in most
studies, a healthy subject is considered to be an individual
with no underlying chronic disease. Beyond ensuring
comparable ages and genders, healthy subjects should also
share the same ethnicity and BMI as well as other envi-
ronmental factors, such as geographical location, diet and
whenever possible, lifestyle (e.g., level of exercise).
Apparently healthy (or disease-free) individuals frequently
take dietary supplements, herbal medicines or over-the-
counter drugs. These can clearly affect the metabolic com-
position of the urine. Therefore, a well-designed study should
track consumption of these apparently ‘‘innocuous’’ com-
pounds. In some cases, evidence of these compounds can be
detected in the urine; however, without reference spectra for
the compounds, their identity is often unknown. Finally, is
worth mentioning that an individual can effectively act as his/
her own control. This approach should encourage the devel-
opment of metabolomics baseline screening as a routine
procedure for large populations. When an individual is
compared with his/herself, especially before the onset of the
disease or before an intervention study, the variability is
largely reduced, and the validity of the statistical analysis is
improved (Westerhuis et al. 2010; Jansen et al. 2005). Careful
attention should also be paid when collecting samples from
patients who suffer from other diseases or with severe health
conditions. As a general rule, no sample should be considered
from ‘‘diseased’’ subjects who suffer from other obvious
diseases apart from the target disease of interest.
5.2 Sample storage
Metabolomics researchers use a wide variety of methods
and protocols to store urine samples. Many use freezing for
long-term storage but the storage conditions may vary
between different laboratories and even within the same lab
or the same study. The effect of storage conditions on the
metabolic composition of urine has been extensively
studied using proton NMR-based metabolomics (Lauridsen
et al. 2007). The results from this study showed that
metabolite levels in human urine samples that were stored
at or below -25 C did not change during 26 weeks of
storage time. On the other hand, formation of acetate was
observed in some urine samples stored at 4 C without the
addition of any preservation agent. These changes were
apparently due to microbial contamination because differ-
ent urine samples have different microbial compositions
(Lauridsen et al. 2007). The use of a 0.22 lm filter was
recommended as a further step to separate urine from
bacterial contaminants (Lauridsen et al. 2007; Gika et al.
2007; Saude and Sykes 2007; Barton et al. 2008). It is
generally recommended that investigators use filtration
and/or gentle centrifugation before freezing their urine
samples to avoid the breakage of human or bacterial cells
that may be present in the sample (Bernini et al. 2011b).
Release of enzymes from cells induces changes in the
metabolite composition and pH over time. Adding a pre-
servative agent such as sodium azide (0.01–0.1 %) is also
commonly used prior to urine storage because it can have
an inhibitory effect on residual bacterial or enzymatic
activity. For comparative studies, it is crucial to use iden-
tical types of collection tubes, filters and storage proce-
dures according to an optimized standard operating
procedure (SOP). Indeed, several reports have shown that
microbial contamination and sample storage at 4 C would
lead to significant changes in the metabolic profile of urine
samples and thus standardization of collection and storage
of urine samples is strongly advised (Rasmussen et al.
2011; Ryan et al. 2011; Saude and Sykes 2007). It is also
known that some urine analytes are sensitive to light. In the
clinical literature, amber-colored urine containers are
occasionally recommend to protect specimens from light,
especially for certain kinds of urine tests (Delanghe and
Speeckaert 2014). To the best of our knowledge, no sys-
tematic evaluation of the effect of the light on the urinary
metabolome has been performed. To avoid repeated
freezing/thawing cycles and repeated long-term exposure
to light, urine samples should be split and stored as mul-
tiple, small aliquots (Bernini et al. 2011).
5.3 Salt and pH optimization
Depending on the person’s acid–base status, the pH value
of normal human urine ranges from 5 to 8 (Martin Her-
nandez et al. 2001; Rylander et al. 2006; Welch et al.
2008). Compounds with chemical groups (such as imida-
zoles) that have pKa values near the physiological range
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are particularly sensitive to pH changes. Consequently, pH
changes can lead to significant chemical shift changes in
the NMR signals of these molecules (Xiao et al. 2009).
Likewise, some polyvalent carboxylates (such as citrate)
are particularly good at chelating metal cations. Conse-
quently, these compounds exhibit significant chemical shift
changes as the salt concentrations change (Bernini et al.
2011b; Foxall et al. 1992). Thus, it is crucial to adjust the
pH of all urine samples prior to any NMR measurements.
In many studies, a phosphate buffer is frequently used to
maintain the desired pH value (Bernini et al. 2011b; Ass-
falg et al. 2008; Bernini et al. 2009). In one recent study, it
was found that even with a concentration of 150 mM
phosphate at pH 7.0, the pH values of urine vary approx-
imately between 6.8 and 7.2 (Rist et al. 2013). Different
approaches can be implemented to overcome the residual
pH variation problem including the use of higher buffer
concentrations (Lauridsen et al. 2007) and adjusting the pH
by adding a small volume of acid, such as HCl, or a small
volume of a concentrated base, such as NaOH (Bertram
et al. 2007b). However, forcing the urine’s pH to a constant
value can hide physiological or pathological information
encoded in the pH changes. To eliminate the variations on
the chemical shift resulting from inter-sample differences
in divalent cation concentrations such as (Ca?2 and Mg?2),
pre-precipitating with KF followed with adding deuterated
EDTA was proposed (Jiang et al. 2012). It has been also
recommended to use K2HPO4 instead of Na2HPO4 where
high concentrations of buffer are needed to overcome the
low solubility of Na2HPO4. In this case one can use buffer-
urine ratio of 1:10 instead of traditionally 1:2, with better
signal to noise ratio (Xiao et al. 2009).
If the ultimate goal is to move research from the
benchtop to clinical practice, metabolomics researchers
need to use well-standardized experimental conditions
including standardized or optimized pH values. To avoid
any sample preparation and/or instrumental variation that
may lead to chemical shift differences, it is also highly
recommended that a standard reference for chemical shift
calibration be added. For proton and carbon NMR mea-
surements of urine samples, both 4,4-dimethyl-4-sila-
pentane-1-sulfonic acid (DSS) or its sodium salt and
3-trimethylsilylpropionic acid (TSP) can be used. DSS is
known to be much less pH sensitive, but it is somewhat
more hydrophobic than TSP. This hydrophobicity can lead
to DSS binding (to proteins or lipids), which broadens the
DSS reference line.
5.4 Experimental temperature
Temperature is another important factor affecting chemical
shifts in metabolites, particularly in metabolites containing
amide groups. Amide groups can form hydrogen bonds,
and when the temperature is changed, the NMR chemical
shifts of amide groups and the adjacent protons can vary,
causing problems for later data analysis. In addition, tem-
perature also impacts the T1 and T2 relaxation of metabo-
lites. T2 relaxation is associated with the line-width of
NMR signals, whereas T1 relaxation is related to NMR
signal intensities. Hence, temperature variation can lead to
problems in the quantification of metabolites. Therefore, in
terms of data quality, it is vital to keep the temperature
constant in all NMR acquisitions. It is usually convenient
to keep the temperature at 25 C (298 K). To ensure
temperature equilibration samples should be left in the
NMR probe for 10 min prior to spectral acquisition; a
longer time is needed if an automated sample exchanger
with cooling rack is used.
6 The metabolomics society and standardization
initiatives
Several parallel metabolomics standardization efforts
started as early as 2004, and by 2007 these efforts were
gathered under the umbrella of the Metabolomics Society
and rebranded as the Metabolomics Standards Initiative
(MSI) (Salek et al. 2013c; Fiehn et al. 2007; Sumner et al.
2007). One major outcome was standardization on report-
ing metabolomics experiments with a set of minimum
information guidelines, including a reporting requirement
for NMR-based experiment data acquisition. In 2012, an
FP7-funded EU Initiative called coordination of standards
in metabolomics (COSMOS) was set up to bring together
leading researchers and bioinformaticians of the European
metabolomics community, members of the Metabolomics
Society, along with other stakeholders worldwide to
develop data infrastructure guidelines and workflows for a
broad range of metabolomics applications (www.cosmos-
fp7.eu). COSMOS also realizes that the potential of met-
abolomics cannot be exploited without major standardiza-
tion of formats and terminologies. To work on commonly
agreed-upon metabolomics data standards, the COSMOS
initiative has gathered metabolomics and bioinformatics
experts to establish a common data exchange format
(syntax) and data semantics that maximize interoperability
with other omics standards. This is achieved by using the
general-purpose Investigation/Study/Assay tabular format
(ISA-Tab) (Rocca-Serra et al. 2010) for experimental meta
data information and adapting the xml-based formats for
the instrument derived ‘‘raw’’ data types by the Proteomics
Standards Initiative (PSI) (Orchard et al. 2003; Hermjakob
et al. 2003). Data completeness is verified by using and
extending the MSI Core Information for Metabolomics
Reporting (CIMR http://biosharing.org/bsg-000175).
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7 Recommendations
Based on an extensive review of the literature (summa-
rized, in part, here) as well as discussions and agreements
reached among the authors we wish to propose the fol-
lowing ‘‘best practice’’ recommendations regarding the
collection, storage and NMR analysis of urine samples for
the purposes of NMR-based metabolomics.
– Ethical guidelines Before collecting any urine sample,
ethical approval from the local research committee
should be obtained. All donors must read and sign an
informed consent, according to the ethical guidelines
and privacy regulations associated with a given insti-
tution. As the ultimate goal is to generate reproducible
data that can be exchanged between different groups it
would reasonable to have a common ethical guideline
proposed by Metabolomics Society, stating that donors
are aware and they have agreed on sharing their sample
data between different groups for research purposes.
– Standard operating protocols (SOPs) The NMR met-
abolic fingerprint of sera/plasma and urine samples was
monitored to establish the optimal standard operating
procedures (SOPs) for pre-analytical handling of these
biofluids for metabolomic studies and biobanks (Bertini
et al. 2011b). The authors proposed the following
procedures for the optimal processing and management
of urine samples: (1) removal of cells and particulate
matter through the combined use of a mild pre-
centrifugation step at 1,000–3,000 rpm (5 min at
4 C) using a 0.22 micron filter; (2) long-term storage
of samples in liquid nitrogen (or liquid nitrogen vapor)
to avoid the lysis of residual cells; (3) fast processing
(within 2 h of collection); and (4) storage at 4 C
between collection and processing. In the opinion of the
authors, the addition of additives (such as enzyme
inhibitors) should be avoided because the required
concentrations introduce unwanted signals in the NMR
spectra that would mask the resonances of metabolites
of interest and may also induce changes in pH, ionic
strength, etc. that affect the original NMR profiles.
– Consumables use one brand of consumables for all
samples (e.g., containers for sample collection and
storage, sample preparation tubes, filtration devices and
NMR tubes). Note that collection and storage tubes as
well as filtration units may contain impurities such as
polyethylene glycol, so they should be screened to
establish their purity prior to use.
– Sample or patient selection detailed criteria for sample/
patient selection should be included in the Methods
section or the experimental protocol. For example,
samples collected from patients with other diseases or
confounding conditions (such as kidney failure,
diabetes and any metabolic disorders) apart from the
target disease should be excluded from diagnostic
studies. If possible, good quality dietary, dietary
supplement and drug intake information should also
be collected for each individual. Dietary information
may be obtained through food frequency question-
naires, while drug intake and dietary supplement
information may be obtained through direct patient
queries. The minimum information required from each
participant for diagnostic investigations (age, gender,
ethnicity, BMI, smoking status, etc.) is proposed in
Table 2.
– Sample collection urine should be collected in the
morning (preprandial). To avoid contamination from
urethral bacteria, only mid-stream urine should be
collected. At least 15 mL of urine should be collected
in a sterile polyethylene tube. Sample tubes must be
leak-proof and tightly sealed. The samples should be
processed and aliquoted within 2 h from the collection,
but preferably faster. Samples must be kept refrigerated
at 4 C prior to processing and must not be frozen prior
to processing (Bernini et al. 2011b).
– Centrifugation urine samples should be centrifuged at
1,000–3,000 rpm (5 min at 4 C) and then filtered
using a 0.22 lm filter before aliquoting and storage
(Bernini et al. 2011b) using appropriately labeled
cryovials


































* Waist–hip ratio is significant factor in studies that involve obesity
and obesity related disease such as diabetes and cardiovascular (de
Koning et al. 2007; Czernichow et al. 2011; Chan et al. 2003; Shah
et al. 2009)
** (SNP) Single-nucleotide polymorphism
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– Additives ideally, urine samples should be free of
externally added chemicals or enzymes to reduce
interference with metabolite signals. However, addition
of micromolar quantities of inorganic bacteriostatic
agents such as sodium azide (to limit bacterial growth)
is appropriate and justified. The addition of small
(*1 mM) amounts of EDTA (Jiang et al. 2012) has
also been shown to reduce paramagnetically induced
chemical shift variability among certain compounds,
thereby giving greater spectral reproducibility.
– Sample freezing dry ice should not be used to freeze
urine samples (Rist et al. 2013). For short-term storage
(\2 weeks), samples can be stored at -20 C. For
long-term storage, urine samples should be stored at -
80 C using an appropriate freezer. If possible, for very
long-term storage, it is better to keep the samples in
liquid nitrogen vapor (Bernini et al. 2011b).
– Sample transfer if samples must be transferred or re-
aliquoted, it is important to maintain the cold chain
during transport, storage and delivery using appropriate
cryogenic storage dewars.
– Chemical shift referencing and locking small amounts
(\1 mM) of DSS (preferred) or TSP (second choice)
should be added to urine samples prior to NMR spectral
acquisition. 5–10 % D2O (as part of the pH buffer)
should also be added to all urine samples to permit
signal locking.
– pH urine samples should be appropriately buffered with
a non-organic buffer (i.e., 100–150 mM phosphate) and
brought to a pH between 6.8 and 7.4. Details of the
buffering process and pH adjustment protocol should
be provided. If samples must be analyzed at very low
pH values (to detect certain compounds) or without
modification of the pH, this information must be
provided and appropriately justified.
– Sample numbers unlike animal models or cell line
experiments, where experimental and environmental
conditions can be well controlled, human studies do not
have the same controls. Consequently, larger numbers
of samples are necessary to mitigate inter- and intra-
sample variations. The number of samples used in
different studies can vary significantly, depending on
the strength of differentiating signals. Ideally, the
number of the samples used should be justified during
the experimental planning phase, using appropriate
power calculations. However, in exploratory or pilot
studies where statistical information for power calcu-
lations is not available, a good rule of thumb is to use
*30 samples and *30 controls.
– Sample randomization If larger numbers of samples are
being studied ([10), spectral acquisition should be
performed after sample randomization, in order to
avoid biasing results due to instrument conditions or
operator differences.
– Magnetic field although NMR-based metabolomics stud-
ies on urine would benefit from the use of the highest
accessible fields, to date most NMR-based metabolomic
studies have been conducted using 600 MHz NMR
spectrometers, as these instruments offer a good com-
promise between sensitivity, resolution and cost.
– Pulse sequences most applications of NMR for meta-
bolomics research rely on 1D NMR experiments. The
technique used for water suppression is critically
important for the comparability between NMR data.
Results obtained from multivariate analysis of NMR
spectra taken under different solvent suppression
conditions can be erroneously interpreted as biological
differences (Potts et al. 2001) if water suppression
artifacts are not carefully excluded. The most used 1D
NMR pulse sequence in urine metabolomics is 1D-
noesypresat (Kumar et al. 1980). Longer acquisition
times (4 s) and shorter delays (*1 s) appear to produce
the best results regarding maximal metabolite signal
intensity and minimal water signal. Shimming: While
automated shimming options in new NMR spectrom-
eters have made metabolomic data collection relatively
quick and easy, manual shimming might be necessary
to improve the quality of spectra. Adjustment of the
field and lock position/phase during the shimming
process should also improve the signal quality (signal-
to-noise, peak symmetry and line width). The shims
can be optimized by assessing line shape and width at
half height of the reference signal, where the line width
of standards such as DSS or TSP should yield a signal
between 0.5 and 1.0 Hz.
– Temperature it is known that variation of experimental
temperature can affect the chemical shift of metabolites,
to differing extents (Hongting Cao 2008). Thus, it is
crucial to standardize and maintain the NMR experimen-
tal temperature. We propose 298 K as the standard
temperature, which is close to average room temperatures
such that the experimental temperature may be easily
maintained during the course of the experiment when
many samples are usually involved. To ensure tempera-
ture equilibration, samples should remain in the NMR
probe for 10 min before spectral acquisition and a longer
time is needed when an automated sample exchanger with
a cooling rack is used for loading a sequence of samples.
– Minimum experimental and instrumental reporting
standards for the sake of creating comparable and
exchangeable NMR data between different groups, it is
important to standardize the minimum experimental
details including sample selection, collection, storage
and preparation along with reporting NMR parameters
Standardizing the experimental conditions for using urine in NMR 885
123
as proposed by the Metabolomics Standards Initiative
(Sumner et al. 2007). This enables the interrogation and
comparison of NMR data as well as facilitating
experimental replication (Sumner et al. 2007).
– Reporting new bio-markers In addition to careful
consideration of all factors that may influence metabolite
concentrations in human urine, researchers should pay
extra attention when reporting new disease biomarkers
derived from urinary measurements. In particular, we
propose that new urinary biomarkers should be abso-
lutely quantified or quantifiable, they should be appro-
priately normalized (using creatinine, specific gravity or
other accepted methods), they should be robust towards
the identification of the disease (sensitivity and/or
specificity [0.7), they should have a well-defined
formula, threshold or decision algorithm that is clearly
stated and the biomarker(s) should be validated using
different populations (differing in geographic location,
age, gender and/or ethnicity), including populations with
potentially confounding disease states or symptoms.
8 Concluding remarks
Human diseases lead to different variations in metabolite
concentrations that are directly correlated with disease
progression. For example, if the concentration of certain
metabolites increases as a result of disease status, these
changes can provide valuable information about the pro-
gression of the disease. Furthermore, a disturbance in
metabolite levels could happen before the onset of clinical
symptoms, thereby making the marker(s) useful for disease
prediction. In addition to disease diagnosis, prognosis and
prediction, the identification of novel disease fingerprints
and biomarkers is also proving to be important in
increasing our understanding of disease pathology and in
monitoring treatment efficacy. Despite the general success
of using NMR-based metabolomics of urine in distin-
guishing between healthy and diseased individuals, novel
biomarker discovery remains an on-going challenge. Sev-
eral factors such as lifestyle, diet, ethnicity, general health
condition, sample selection, sample storage, and sample
preparation can alter metabolite concentrations in urine,
leading to major problems that may complicate and inter-
fere with a study. In an effort to mitigate these problems,
we have conducted a broad survey of the literature and
investigated (within our labs) some of the current practices
for NMR-based metabolomics studies of urine. Based on
this information, we have identified a number of best
practices and have compiled a series of recommendations
for conducting NMR-based metabolomic studies of urine.
In presenting and justifying these recommendations, we
hope that the metabolomics community will adopt them as
part of their standard experimental and publication routine.
These best-practice recommendations certainly could go a
long way to help the metabolomics community translate
important discoveries from the lab into the clinic.
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